Tirzepatide Unlikely to Exacerbate DR in First Year of Treatment

Tirzepatide, recently FDA-approved for weight loss, offers substantial metabolic benefits and may be useful for patients with DR. Photo: Eli Lilly. Click image to enlarge. The popular drug tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown great benefits in glycemic control, weight loss and cardiometabolic outcomes compared to GLP-1 RA drugs alone. Still, evidence regarding its effect on the development and progression of diabetic retinopathy (DR) in real-world populations remains limited. Researchers at Weill Cornell Medicine in New York evaluated if tirzepatide was associated with incident or progressive diabetic retinopathy and related complications using data from a large multicenter electronic health-record network.The team determined that starting tirzepatide treatment was associated with a lower 12-month risk of incident mild nonproliferative DR (NPDR) and with fewer vision-threatening events, proliferative DR (DR), diabetic macular edema (DME), vitreous hemorrhage, tractional retinal detachment and need for intravitreal anti-VEGF or panretinal photocoagulation.After propensity matching for demographic, metabolic and systemic covariates, 173,846 patients were included in the analysis (86,923 per cohort; mean age: 56.9 years; 52.0% women).Incident mild NPDR occurred in 0.490% of tirzepatide users vs. 1.2% of lifestyle intervention alone controls (risk ratio; RR: 0.86). The researchers also found similar risk reductions for PDR (RR: 0.71) and DR with macular edema (RR: 0.62). The tirzepatide cohort also had a smaller incidence of severe NPDR, but it did not reach significance. Tirzepatide users were also less likely to experience complications such as vitreous hemorrhage (RR: 0.61) and tractional retinal detachment (RR: 0.37). The cohort also had a lower need for intravitreal anti-VEGF injections (RR: 0.90) or panretinal photocoagulation (RR: 0.61). The tirzepatide cohort also had a reduced need for pars plana vitrectomy, but it did not reach significance.“Dual agonism enhances insulin sensitivity and energy expenditure beyond GLP-1 monotherapy,” the study authors wrote in their paper, which was published in Ophthalmology. “This dual mechanism may explain the absence of early-worsening effects and the apparent protective association observed in our real-world cohort.”They concluded that prospective studies that incorporate standardized retinal imaging and extend follow-up are needed to confirm the durability of this benefit and to refine recommendations for patients considering weight loss medications who are at risk for DR.Click here for the journal source. Shah J, Razavi P, Festok M, et al. Tirzepatide and reduced risk of diabetic retinopathy and related complications: a multicenter US cohort study. Ophthalmology. January 21, 2026. [Epub ahead of print]. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.